Metabolite profiles of diabetes mellitus and response to intervention in anti-hyperglycemic drugs

Front Endocrinol (Lausanne). 2023 Oct 31:14:1237934. doi: 10.3389/fendo.2023.1237934. eCollection 2023.

Abstract

Type 2 diabetes mellitus (T2DM) has become a major health problem, threatening the quality of life of nearly 500 million patients worldwide. As a typical multifactorial metabolic disease, T2DM involves the changes and interactions of various metabolic pathways such as carbohydrates, amino acid, and lipids. It has been suggested that metabolites are not only the endpoints of upstream biochemical processes, but also play a critical role as regulators of disease progression. For example, excess free fatty acids can lead to reduced glucose utilization in skeletal muscle and induce insulin resistance; metabolism disorder of branched-chain amino acids contributes to the accumulation of toxic metabolic intermediates, and promotes the dysfunction of β-cell mitochondria, stress signal transduction, and apoptosis. In this paper, we discuss the role of metabolites in the pathogenesis of T2DM and their potential as biomarkers. Finally, we list the effects of anti-hyperglycemic drugs on serum/plasma metabolic profiles.

Keywords: amino acids; carbohydrates; diabetes mellitus; lipids; metabolites.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acids, Branched-Chain / metabolism
  • Diabetes Mellitus, Type 2* / metabolism
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Insulin Resistance* / physiology
  • Quality of Life

Substances

  • Amino Acids, Branched-Chain
  • Hypoglycemic Agents

Grants and funding

This research was funded by Natural Science Foundation of Fujian Province (2017J01627), and China Postdoctoral Science Foundation (2021M700782).